



Attorney Docket No. MSU 4.1-672
Appl. No. 10/725,214
Amdt. dated: June 23, 2006
Reply to Office Action of April 27, 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appln. No. : 10/725,214 Confirmation No. 4443
Applicants : Muraleedharan G. Nair, Yanjun Zhang
and Shaiju K. Vareed
Filed : December 1, 2003
Title : METHOD FOR INHIBITING CANCER CELLS
TC/A.U. : 1655
Examiner : Michele C. Flood
Docket No. : MSU 4.1-672
Customer No. : 21036

MAIL STOP RCE
COMMISSIONER FOR PATENTS
P. O. BOX 1450
ALEXANDRIA VA 22313-1450

DECLARATION UNDER 37 C.F.R. § 1.132

Dear Sir:

Muraleedharan G. Nair states as follows:

(1.) That he is an inventor of the invention in the
above entitled application.

Attorney Docket No. MSU 4.1-672
Appl. No. 10/725,214
Amdt. dated: June 23, 2006
Reply to Office Action of April 27, 2006

(2.) That he is a Professor of Horticulture & Food Safety & Toxicology at Michigan State University, East Lansing, Michigan 48824.

(3.) That the colon cell line designated "HCT-116" was purchased from the American Type Culture Collection (Rockville, Md.).

(4.) That "HCT-116" is a human cell line derived from a colorectal carcinoma of the colon as evidenced by the attached product description of the American Type Culture Collection (Rockville, Md.).

(5.) That the stomach cell line designated "AGS" was purchased from the American Type Culture Collection (Rockville, Md.).

(6.) That "AGS" is a human cell line derived from a gastric adenocarcinoma of the stomach as evidenced by the attached product description of the American Type Culture Collection (Rockville, Md.).


Attorney Docket No. MSU 4.1-672
Appl. No. 10/725,214
Amdt. dated: June 23, 2006
Reply to Office Action of April 27, 2006

(7.) That "HCT-116" is an *in-vitro* model that is recognized as correlating to the specific condition of colon cancer as evidenced by the enclosed publication, Giese et al. "The influence of tumor size and environment on gene expression in commonly used human tumor lines", *BMC Cancer*. 2004 Jul 15;4:35.

(8.) That "AGS" is an *in-vitro* model that is recognized in the art as correlating to the specific condition of stomach cancer as evidenced by the enclosed abstracts, Barranco et al. "Heterogeneous responses of an *in vitro* model of human stomach cancer to anticancer drugs", *Invest. New Drugs* 1: 117-127, 1983, and Barranco et al. "Establishment and characterization of an *in vitro* model system for human adenocarcinoma of the stomach", *Cancer Res.* 43: 1703-1709, 1983.

Attorney Docket No. MSU 4.1-672
Appl. No. 10/725,214
Amdt. dated: June 23, 2006
Reply to Office Action of April 27, 2006

(9.) That the undersigned declares further that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.



Muraleedharan G. Nair

Date: 6/23/06